Clinical trials: Cutaneous Lupus, open to volunteers
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Research Accelerated by You Lupus Registry
Summary The Lupus Foundation of America (LFA) Research Accelerated by You (RAY) Registry is a fully remote, longitudinal registry designed to collect data from adults and children living with lupus.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
- Trial name
- RAY (NCT06927219)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Lupus Foundation of America
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- ELOWEN-1 (NCT07332481)
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 74 sites in United States, Australia and 18 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Discoid Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid…
- Trial name
- NCT07557927
- Testing
- Dihydroartemisinin tablets, Hydroxychloroquine tablets
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- Kunming Pharmaceuticals, Inc.
Cutaneous Lupus Erythematosus(CLE)
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
- Trial name
- NCT07749651
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- NCT07355218
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 70 sites in United States, Australia and 18 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..
This study is a Phase Ia, single-center, randomized, double-blind, dose-escalation, placebo-controlled clinical trial designed to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profile of ACT100 in…
- Trial name
- NCT07408908
- Testing
- ACT100 Injection
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
The primary objective of this phase Ib study is to evaluate the safety and tolerability of multiple-ascending, subcutaneous (SC) doses of HC022 in SLE/CLE subjects.
- Trial name
- NCT07306585
- Testing
- HC022
- Where
- China
- Volunteers
- 32 people
- Sponsor
- HC Biopharma Inc.
Cutaneous Lupus Erythematosus (CLE)
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
The Cutaneous Lupus Erythematosus (CLE) database, established in 2006, is a multi-site database between the University of Pennsylvania and the University of Texas Southwestern (UTSW).
- Trial name
- NCT01510067
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
Discoid Lupus Erythematosus
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.
- Trial name
- NCT06261021
- Testing
- Ruxolitinib 1.5% cream, Application without occlusion in Area 1, Application under occlusion at night in Area 2
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Innovaderm Research Inc.
Cutaneous Lupus Erythematosus
Tapinarof for Cutaneous Lupus Erythematosus
The investigators hypothesize that topical application of Tapinarof, an FDA-approved topical Aryl hydrocarbon receptor (AHR) agonist for the treatment of plaque psoriasis, would inhibit lupus-causing T cells and lead to…
- Trial name
- NCT06661213
- Testing
- Tapinarof
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus
This study is evaluating whether afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8 (TLR7/TLR8), can improve skin disease in adults with active cutaneous lupus erythematosus (CLE), with or…
- Trial name
- DISCOVERY (NCT07881120)
- Testing
- Afimetoran
- Where
- 3 sites in United States
- Volunteers
- 390 people
- Sponsor
- Beeline Medicines Corporation
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation
Diagnosis and follow up of a lupus cohort in a multidisciplinary consultation in Brest ( France)
- Trial name
- CO LUPUS (NCT04320680)
- Testing
- description of a lupus patient cohort
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator…
- Trial name
- ROSY-S (NCT07691970)
- Testing
- Anifrolumab
- Where
- 153 sites in United States, Argentina and 33 more
- Volunteers
- 1,072 people
- Sponsor
- AstraZeneca
Cutaneous Lupus Erythematosus (CLE)
This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE
This study aims to evaluate the efficacy and safety of subcutaneous (SC) 626 versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
- Trial name
- NCT07900867
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Systemic Lupus Erythematosus, Cutaneous Lupus
Duke Lupus Registry
Lupus is a systemic autoimmune disease that can present with many varied symptoms, including joint pain, fevers, kidney disease, and rashes. Lupus can affect anyone, but it is most common in younger women.
- Trial name
- NCT00512694
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Duke University
Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases
Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases.
- Conditions
- Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases, Auto-inflammatory Dermatological Diseases, Skin Diseases
- Trial name
- TekAPo (NCT06387654)
- Testing
- Blood sampling, Remainders of samples taken as part of the treatment
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Toulouse
Lupus Erythematosus
Cutaneous Lupus Registry
Approximately 1.4 million individuals in the United States have systemic lupus erythematosus, and about 85% of these individuals develop skin lesions at some point of their disease.
- Trial name
- NCT01266915
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cutaneous Lupus Erythematosus (CLE)
A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus
The research study is being conducted to learn more about how patients with cutaneous lupus erythematosus (CLE) respond to the use of quinacrine.
- Trial name
- NCT07694336
- Testing
- Quinacrine Hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Victoria Werth
Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed…
- Trial name
- NCT06875960
- Testing
- BMS-986165
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Autoimmune Diseases, Rheumatoid Arthritis (RA)
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in…
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO)
- Trial name
- NCT07455578
- Testing
- S-4321
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Seismic Therapeutic AU Pty Ltd